Protagonist Therapeutics, Inc. $PTGX Shares Sold by WINTON GROUP Ltd

Posted by Geri Gentry on Jun 10th, 2026

WINTON GROUP Ltd lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 38.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,471 shares of the company’s stock after selling 7,090 shares during the quarter. WINTON GROUP Ltd’s holdings in Protagonist Therapeutics were worth $1,002,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Smartleaf Asset Management LLC lifted its position in shares of Protagonist Therapeutics by 11.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,403 shares of the company’s stock worth $91,000 after purchasing an additional 146 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Protagonist Therapeutics by 1.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock worth $1,170,000 after purchasing an additional 193 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Protagonist Therapeutics by 8.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock worth $258,000 after purchasing an additional 221 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its position in shares of Protagonist Therapeutics by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 61,849 shares of the company’s stock worth $4,109,000 after purchasing an additional 253 shares in the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Trading Up 8.0%

PTGX stock opened at $105.87 on Wednesday. Protagonist Therapeutics, Inc. has a twelve month low of $49.38 and a twelve month high of $107.84. The company’s 50 day moving average is $101.38 and its two-hundred day moving average is $92.78. The stock has a market cap of $6.81 billion, a P/E ratio of -58.49 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The company had revenue of $56.37 million for the quarter, compared to analysts’ expectations of $11.70 million. On average, equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Truist Financial increased their price target on shares of Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $121.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. TD Cowen raised their target price on shares of Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Citizens Jmp raised their target price on shares of Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Finally, JPMorgan Chase & Co. raised their target price on shares of Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a report on Thursday, March 19th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $115.21.

Read Our Latest Research Report on Protagonist Therapeutics

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 9,000 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $99.64, for a total transaction of $896,760.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $779,683. This trade represents a 53.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the sale, the chief executive officer directly owned 523,478 shares in the company, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 263,345 shares of company stock valued at $26,707,266 in the last quarter. Company insiders own 5.19% of the company’s stock.

About Protagonist Therapeutics

(Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.